| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Pharmacy, Kyoto University Hospital, Kyoto, Kyoto, Japan
2 Department of Urology, Kyoto University Hospital, Kyoto, Kyoto, Japan
3 Division of Artificial Kidneys, Kyoto University Hospital, Kyoto, Kyoto, Japan
4 Department of Clinical Biology and Medicine, University of Tokushima, Tokushima, Tokushima, Japan
* To whom correspondence should be addressed. E-mail: inui{at}kuhp.kyoto-u.ac.jp.
A H+/organic cation antiporter (multidrug and toxin extrusion 1: MATE1/SLC47A1) plays important roles in the tubular secretion of various clinically important cationic drugs such as cimetidine. We have recently found that the regulation of this transporter greatly affects the pharmacokinetic properties of cationic drugs in vivo. No information is available about the regulatory mechanisms for the MATE1 gene. In the present study, therefore, we examined the gene regulation of human (h) and rat (r) MATE1 focusing on basal expression. A deletion analysis suggested that the regions spanning -65/-25 and -146/-38 were essential for the basal transcriptional activity of the hMATE1 and rMATE1 promoter, respectively, and that both regions contained putative Sp1-binding sites. Functional involvement of Sp1 was confirmed by Sp1 overexpression, a mutational analysis of Sp1-binding sites, mithramycin A treatment, and an electrophoretic mobility shift assay (EMSA). Furthermore, we found a single nucleotide polymorphism (SNP) in the promoter region of hMATE1 (G-32A), which belongs to a Sp1-binding site. The allelic frequency of this rSNP was 3.7%, and Sp1-binding and promoter activity were significantly decreased. This is the first study to clarify the transcriptional mechanisms of the MATE1 gene and to identify a SNP affecting the promoter activity of hMATE1.
This article has been cited by other articles:
|
|
 |
|
  M. Tsuda, T. Terada, T. Mizuno, T. Katsura, J. Shimakura, and K.-i. Inui Targeted Disruption of the Multidrug and Toxin Extrusion 1 (Mate1) Gene in Mice Reduces Renal Secretion of Metformin Mol. Pharmacol., June 1, 2009; 75(6): 1280 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Becker, L. E. Visser, R. H.N. van Schaik, A. Hofman, A. G. Uitterlinden, and B. H.Ch. Stricker Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study Diabetes, March 1, 2009; 58(3): 745 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kajiwara, T. Terada, J.-i. Asaka, M. Aoki, T. Katsura, I. Ikai, and K.-i. Inui Regulation of basal core promoter activity of human organic cation transporter 1 (OCT1/SLC22A1) Am J Physiol Gastrointest Liver Physiol, December 1, 2008; 295(6): G1211 - G1216. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
